|
05/07/21
|
Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults
Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine Safety and immunogenicity data to also inform oral COVID-19 vaccine program in older population SOUTH
|
|
05/04/21
|
Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study
Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study results may inform the COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif.
|
|
05/03/21
|
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
Vaxart oral vaccine induced higher CD8 + T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa, show broad cross-reactivity SOUTH SAN FRANCISCO, Calif.
|
|
05/03/21
|
Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update
Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/II Four clinical trials of the oral norovirus vaccine candidate to be initiated in 2021 Cash, cash equivalents, and
|
|
04/29/21
|
Vaxart to Present at the World Vaccine Congress Washington 2021
SOUTH SAN FRANCISCO, Calif. , April 29, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean
|
|
04/26/21
|
Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines
Vaxart to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants SOUTH SAN FRANCISCO, Calif. , April 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant
|
|
04/23/21
|
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif. , April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon , M.D., to its Board
|
|
04/22/21
|
Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans
Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds Seven in 10 said they would prefer a pill over an injection SOUTH SAN FRANCISCO, Calif. , April 22, 2021 (GLOBE NEWSWIRE) -- Nearly 19 million more American adults – about a
|
|
03/04/21
|
Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C.
|
|
02/25/21
|
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021 Cash and cash equivalents of $126.9 million as of December 31, 2020 Conference call and webcast focused on our COVID-19 strategy scheduled for Tuesday, March 2,
|
